Harvard Bioscience (HBIO)
(Delayed Data from NSDQ)
$3.30 USD
+0.03 (0.92%)
Updated May 22, 2024 04:00 PM ET
After-Market: $3.32 +0.02 (0.61%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HBIO 3.30 +0.03(0.92%)
Will HBIO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for HBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HBIO
Harvard Bioscience (HBIO) Q1 Earnings Match Estimates
Bruker (BRKR) Q1 Earnings Beat Estimates
HBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Watch These 5 Technology Stocks for Q1 Earnings: Beat or Miss?
Harvard Bioscience (HBIO) Q2 Earnings and Revenues Lag Estimates
Bruker (BRKR) Surpasses Q2 Earnings and Revenue Estimates
Other News for HBIO
Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference
Riverwater Micro Opportunities Strategy Q1 2024 Commentary
Harvard Bioscience Inc (HBIO) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
Harvard Bioscience, Inc. (HBIO) Q1 2024 Earnings Call Transcript
HBIO Stock Earnings: Harvard Bioscience Meets EPS, Misses Revenue for Q1 2024